Blog

Latest news about encapsia

Increased demand for use of encapsia in decentralized trials adds more capabilities to this revolutionary platform

Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity.

We’ve added new capabilities for encapsia, after we’ve seen increased demand for its use in decentralized trials. Encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI.

Encapsia was designed to address the pain around remote collection, integration, and availability of disparate data. This includes powerful visualizations to provide greater oversight, down to the source data level, to allow immediate action and optimize your trial. In one platform you can collect data via the web or iPad app (EDC, Home Visit, and eSource), manage, visualize, and analyze all your clinical data from the portfolio to patient level.

The encapsia team prioritizes enhancements through alignment of client feedback with strategic and environmental changes to the marketplace (e.g., the pandemic). Our project managers and technical consultants operate collaboratively with the client operational teams, holding regular deep-dive governance meetings to support the goals of our clients at both tactical and strategic level.

As biotechnology, pharmaceutical, and medical device companies resumed clinical development in 2020, the new reality necessitated solutions to make managing, interpreting, visualizing, and analyzing data from their clinical programs simpler. This required augmenting and automating clinical research processes to facilitate these decentralized, virtualized, and hybrid trials. Since Q4 2020, we’ve seen a rapid uptake of the encapsia platform, particularly eSource, by sponsors conducting everything from phase I to large scale phase IV studies.

Some of the latest encapsia enhancements include:

  • Ability to add images and files into encapsia EDC – providing evidence to facilitate remote monitoring. Sites use any mobile phone (Android or iOS) to capture images and redact as necessary before upload.
  • EDC supports complex client specific data entry options, together with reports and visualizations directly within the eCRF.
  • Drug supply management and randomization is included through hyper-integration with endpoint Clinical (and other randomization and supply vendors) to offer seamless logistic supply management and randomization to sites.
  • Ability of a user to ‘pin’ their favorite reports/visualizations for immediate access wherever they are in encapsia.
  • Greater options for clients collecting eSource data – more configurable elements, patient mode, and enhanced queries options.
  • New home visit option e.g., for DCT (study nurses visiting patients in their homes).

Dr Timothy Corbett-Clark, Chief Technology Officer, encapsia, commented: “The promise of encapsia is to bring the tech to the data, remove product boundaries, and deliver a holistic, fit for purpose solution that can support the entire development lifecycle. As more data of more types are gleaned from more sources, it all needs to come together for real-time processing during study conduct. That’s what our clients are asking for, and it requires a revolutionary eClinical platform built with the future of clinical research in mind.”


Step Forward with encapsia and let us demonstrate how choosing the right technology can transform your trials of tomorrow.


We assure you it’s like nothing else when it comes to clinical technology. To learn more about how encapsia can support decentralized clinical trials please EMAIL US

Increased demand for use of encapsia in decentralized trials adds more capabilities to this revolutionary platform

Latest articles

It is no secret that there is a digital transformation happening across life sciences and healthcare. This seismic shift is being facilitated by cutting-edge technology that is enabling the interrogation and aggregation of the vast quantities of data that we now have at our fingertips. The adoption of automated processes using technologies like artificial intelligence (AI), which incorporates human intelligence into machines through a set of rules, and machine learning (ML), an application of AI whereby the computer learns automatically through its experiences, is key to collecting and analyzing the vast and varied data that is now available and facilitating a move to a personalized approach to medicine.
As the ways in which clinical trials are conducted and monitored continue to modernize at pace, there is an urgent need for digital transformation in the industry. If sponsors are to realize their goals of running flexible, decentralized trials (DCT), risk-based management (RBM), or adaptive trials while adopting big data, artificial intelligence / machine learning (AI/ML), the emphasis must now be on technology solutions that optimize clinical trial data workflows by bringing the technology to the data.
Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity. We’ve added new capabilities for encapsia, after we’ve seen increased demand for its use in decentralized trials. Encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI. Encapsia was designed to address the pain around remote collection, integration, and availability of disparate data.